Drugs / SHR0534
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03006159 | Mar → Dec 2015 | diabetes mellitus, noninsulin-dependent, 2 | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02750553 | Jan 2015 → Jan 2016 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02749097 | Oct → Dec 2013 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR0534 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03006159 ↗ |
| Route | Oral | “Single oral dose of 10 mg SHR0534 or matching placebo” NCT02749097 ↗ |